High Prevalence of Headaches During Covid‐19 Infection: A Retrospective Cohort Study

Poncet-Megemont, Louis; Paris, P.; Tronchere, Amélie; Salazard, Jean-Pascal; Pereira, Bruno; Dallel, Radhouane; Auméran, C.; Beytout, J.; Jacomet, Christine; Laurichesse, H.; Lesens, Olivier; Mrozek, Natacha; Vidal, M.; Moisset, Xavier

doi:10.1111/head.13923

Cited by 66 publications

(100 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ten studies included people requiring ICU admission during the acute phase. [9,[25][26][27][28][29][30][31][32] The longest follow-up period in any study was a mean of 111 (SD: 11) days post-discharge (Table 2). Most studies did not specify covid-19 severity nor treatment received during the acute phase.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…Most studies did not specify covid-19 severity nor treatment received during the acute phase. Pre-existing comorbidities were reported in half of the studies (54%, 15/28), [9,25,[27][28][29][30][31][33][34][35][36][37][38] with hypertension and diabetes most commonly documented. Symptoms A wide range of new or persistent symptoms were documented in both the hospitalised and non-hospitalised cohorts.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…Quantifying how many people develop 'long covid' is difficult, with some cohorts suggesting only 13% of people are fully recovered from their illness at 60 days post-onset. [9] A patientled social media survey reported that the chance of full recovery by day 50 was smaller than 20%. [10] The symptoms of 'long covid' are equally ill-defined, with some studies characterising it as a fluctuating illness associated with cough and fever, whilst others emphasise chronic chest pain, breathlessness and neuro-cognitive difficulties.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Characterising long term Covid-19: a living systematic review

Michelen

Cheng

Manoharan³

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective To understand the frequency, profile, and duration of persistent symptoms of covid-19 and to update this understanding as new evidence emerges. Design: A living systematic review produced in response to the rapidly evolving evidence base for long covid. Data sources Medline and CINAHL (EBSCO), Global Health (Ovid), WHO Global Research Database on covid-19, LitCOVID, and Google Scholar to 28th September 2020. Study selection Studies reporting long-term symptoms and complications among people with confirmed or suspected covid-19, both in those previously hospitalised and those never hospitalised. Only studies incorporating over 100 participants qualified for data extraction and were assessed for risk of bias. Results were analysed using descriptive statistics. Quality assessment Risk of bias was assessed using a quality assessment checklist for prevalence studies. Results Twenty-eight studies qualified for data extraction; 16 of these were cohort studies, ten cross-sectional, and two large case series. The analysis included 9,442 adults with covid-19 from 13 countries. The longest mean follow-up period was 111 (SD: 11) days post-hospital discharge. A wide range of systemic, cardiopulmonary, gastrointestinal, neurological, and psychosocial symptoms was reported, of which the most common were breathlessness, fatigue, smell and taste disturbance, and anxiety. Persistent symptoms were described across both previously hospitalised and non-hospitalised populations. The quality of evidence was low, with a high risk of bias and heterogeneity in prevalence. The incorporated studies demonstrated limited external validity, a lack of control subjects, and inconsistent data collection methods. Few studies were conducted in primary care, no studies focused solely on children, and no studies were set in low- and middle-income countries. Conclusion: Our findings suggest that long covid is a complex, heterogeneous condition; however, the limited evidence base currently precludes a precise definition of its symptoms and prevalence. There is a clear need for robust, controlled, prospective cohort studies, including different at-risk populations and settings, incorporating appropriate investigations, collected and recorded in a standardised way.

show abstract

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Characterising long term Covid-19: a living systematic review

Michelen

Cheng

Manoharan³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“… 102 , 103 , 107 , 108 The recovery of these symptoms is still undetermined; i.e., it is not yet known whether it is total or partial and what the recovery times are. 103 , 109 , 110 And this question refers to what is perhaps the most important question: will there be neurological sequelae in the medium-to-long-term? Incomplete resolution of chemosensory alterations could indicate future neurodegenerative diseases, as these symptoms are prognostic symptoms of many neurodegenerative diseases.…”

Section: Resultsmentioning

confidence: 99%

Chemosensory Systems in COVID-19: Evolution of Scientific Research

Veronese

Sbarbati

2021

ACS Chem. Neurosci.

View full text Add to dashboard Cite

COVID-19 disease induced by coronavirus SARS-CoV-2 presents among its symptoms alterations of the chemosensory functions. In the first studies on the Chinese population, this symptomatology was not particularly relevant, and hyposmia and hypogeusia were excluded from the symptoms to be evaluated to diagnose the disease. With the pandemic spread of the illness, there has been an augment in reports on chemosensory dysfunctions among patients. The first data analysis showed the presence of these disorders mainly in paucisymptomatic and asymptomatic patients. The interest in chemosensory systems therefore increased considerably, because the olfactory and gustatory symptoms could be the key to stop the infection spread. Furthermore, the degree of alert and attention grew, considering that these types of dysfunctions are prognostic symptoms of serious neurodegenerative diseases. About 9 months have passed since the first anecdotal reports on the involvement of the olfactory and gustatory systems in the COVID-19 pathology. For this reason, a careful review of the literature was conducted to understand if it is clearer which people present chemosensory symptoms and if these are related to the severity of the disease. Furthermore, we have identified which aspects still remain to be clarified.

show abstract

“…After having carried out two tests, which must be negative, as the literature suggests [ 30 ], for the diagnosis of a recovered patient, it is essential to know why some studies [ 31 , 32 ] have reported that after having obtained these two negative tests, patients present symptoms and present in some cases positivity of new tests. Because this phenomenon has been described in different countries [ 24 , 33 , 34 ], it is discussed that cannot be attributed only to false negatives due to the coincides with others studies, so it could be a reactivation or reinfection [ 30 ].…”

Section: Introductionmentioning

confidence: 99%

Persistence of COVID-19 Symptoms after Recovery in Mexican Population

Galván-Tejada

Herrera-García

Godina-González

et al. 2020

IJERPH

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease (COVID-19), a highly contagious infectious disease that has caused many deaths worldwide. Despite global efforts, it continues to cause great losses, and leaving multiple unknowns that we must resolve in order to face the pandemic more effectively. One of the questions that has arisen recently is what happens, after recovering from COVID-19. For this reason, the objective of this study is to identify the risk of presenting persistent symptoms in recovered from COVID-19. This case-control study was conducted in one state of Mexico. Initially the data were obtained from the participants, through a questionnaire about symptoms that they had at the moment of the interview. Initially were captured the collected data, to make a dataset. After the pre-processed using the R project tool to eliminate outliers or missing data. Obtained finally a total of 219 participants, 141 recovered and 78 controls. It was used confidence level of 90% and a margin of error of 7%. From results it was obtained that all symptoms have an associated risk in those recovered. The relative risk of the selected symptoms in the recovered patients goes from 3 to 22 times, being infinite for the case of dyspnea, due to the fact that there is no control that presents this symptom at the moment of the interview, followed by the nausea and the anosmia with a RR of 8.5. Therefore, public health strategies must be rethought, to treat or rehabilitate, avoiding chronic problems in patients recovered from COVID-19.

show abstract

High Prevalence of Headaches During Covid‐19 Infection: A Retrospective Cohort Study

Cited by 66 publications

References 16 publications

Characterising long term Covid-19: a living systematic review

Characterising long term Covid-19: a living systematic review

Chemosensory Systems in COVID-19: Evolution of Scientific Research

Persistence of COVID-19 Symptoms after Recovery in Mexican Population

Contact Info

Product

Resources

About